What do systematic reviews say?

Coasting vs early unilateral follicular aspiration

The review found no eligible studies for this question.

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Coasting vs gonadotrophin‐releasing hormone antagonist

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 190 participants
  Very low

Coasting vs gonadotrophin‐releasing hormone antagonist

The review found no eligible studies for this question.

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Coasting vs gonadotrophin‐releasing hormone antagonist

The review found no eligible studies for this question.

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Coasting vs follicle stimulating hormone administration at time of hCG

It is very uncertain whether coasting changes OHSS compared with follicle stimulating hormone administration at time of hCG (very low certainty).

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  OR 43.74 [2.54, 754.58]
  1 study · 102 participants
  Very low

Coasting vs follicle stimulating hormone administration at time of hCG

The review found no eligible studies for this question.

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Coasting vs no coasting

It is very uncertain whether coasting changes live birth compared with no coasting (very low certainty).

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  OR 0.48 [0.14, 1.62]
  1 study · 68 participants
  Very low

Coasting vs follicle stimulating hormone administration at time of hCG

The review found no eligible studies for this question.

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Coasting vs cabergoline

It is very uncertain whether coasting changes OHSS compared with cabergoline (very low certainty).

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  OR 1.98 [0.69, 5.68]
  2 studies · 120 participants
  Very low

Coasting vs cabergoline

The review found no eligible studies for this question.

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Coasting vs cabergoline

The review found no eligible studies for this question.

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Coasting vs no coasting

It is very uncertain whether coasting changes miscarriage compared with no coasting (very low certainty).

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  OR 0.85 [0.25, 2.86]
  2 studies · 207 participants
  Very low

Coasting vs early unilateral follicular aspiration

It is very uncertain whether coasting changes OHSS compared with early unilateral follicular aspiration (very low certainty).

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  OR 0.98 [0.34, 2.85]
  2 studies · 83 participants
  Very low

Coasting vs early unilateral follicular aspiration

The review found no eligible studies for this question.

• Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Human albumin vs placebo or no treatment

It is very uncertain whether human albumin changes moderate or severe OHSS compared with placebo or no treatment (very low certainty).

• Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
  OR 0.67 [0.47, 0.95]
  7 studies · 1452 participants
  Very low

Mannitol vs placebo / no treatment

The review found no eligible studies for this question.

• Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mannitol vs placebo / no treatment

The review found no eligible studies for this question.

• Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Human albumin vs placebo or no treatment

The review found no eligible studies for this question.

• Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Human albumin vs placebo or no treatment

The review found no eligible studies for this question.

• Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

HES vs placebo or no treatment

It is very uncertain whether HES changes moderate or severe OHSS compared with placebo or no treatment (very low certainty).

• Volume expanders for the prevention of ovarian hyperstimulation syndrome 2016 · Cochrane Headline outcomes only
  OR 0.27 [0.12, 0.59]
  2 studies · 272 participants
  Very low